TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02592317
Drug: Drug Cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug cocktail comprise of midazolam (2 mg), warfarin (10 mg), vitamin K (10 mg), omeprazole (40 mg), and fexofenadine (30 mg) will be administered on Study Day 1 and 43.
Study: NCT02592317
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 15 mg will be administered orally on Study Day 9 and 51.
Study: NCT02209636
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Table identical to lanthanum carbonate but with no active ingredient
Study: NCT02209636
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous administration during measurement of flow mediated dilation.
Study: NCT01644188
Drug: Placebo (for alirocumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
Study: NCT01644188
Drug: Placebo (for ezetimibe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule once daily orally at approximately the same time of the day with or without food.
Study: NCT01644188
Drug: Lipid Modifying Therapy (LMT)
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose.
Study: NCT01310712
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo twice a day for 42 days.
Study: NCT02475876
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Route of administration is IV for all Cohorts. Dosing interval is every 8 hrs. for all Cohorts:~* Cohort 1; No. Subjects = 5; Age 1-5 months; Dose = 9 mg/kg;~* Cohort 2; No. Subjects = 5; Age \>5 months to 1 year; Dose =12 mg/kg;~* Cohort 3; No. Subjects = 5; Age \>1-2 years; Dose =12 mg/kg.~* Cohort 4; No. Subjects = 4; Age \>2-6 years; Dose =12 mg/kg.~* Cohort 5; No. Subjects = 4; Age \>6-12 years; Dose =10 mg/kg.~* Cohort 6; No. Subjects = 4; Age \>12-16 years; Dose =10 mg/kg.
Study: NCT02742532
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal saline solution
Study: NCT02151643
Drug: PT20
Normalized name: GALACTIC PURPLE TETRA TRANSGENIC WHOLE (PT2013 RDNA CONSTRUCT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified ferric oxide adipate tablets
Study: NCT00508274
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is supplied as a biconvex, oblong, light peach and peach colored, film-coated tablets for oral administration.
Study: NCT00526097
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-to-match bisacodyl 10 mg (2 x 5 mg) once daily
Study: NCT04591262
Drug: 14C-PF-06826647 100 ug IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14C-PF-06826647 100 ug IV
Study: NCT01709123
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill for chromium niacinate
Study: NCT01660919
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01660919
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00038298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given 3 times weekly
Study: NCT00038298
Drug: AGM 719
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg 3 times weekly
Study: NCT00038298
Drug: placebo to AMG 719
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dose given 3 times weekly
Study: NCT02547519
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total of 12 months treatment; daily treatment with insulin or placebo capsules containing filling substance (microcrystalline cellulose).
Study: NCT03639922
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of placebo per day for 6 days
Study: NCT03444467
Drug: NNC9204-1513
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive NNC9204-1513 subcutaneous (s.c., in to a skin fold on the stomach) injection as single increasing doses of 0.01 mg, 0.04 mg, 0.10 mg, 0.25 mg, 0.50 mg, 1.0 mg or 2.0 mg. Each participant will only be given one dose.~Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group.
Study: NCT03444467
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single dose of placebo (for double dummy injections).
Study: NCT03401918
Drug: Oral antibiotics and vaginal probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: For subjects with abnormal microbiome results, oral antibiotics and vaginal probiotic treatment will be offered followed by a repeat uterine microbiome biopsy.
Study: NCT02418585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase.
Study: NCT04080752
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered orally.
Study: NCT03018223
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Reduced intensity conditioning: 14.5 mg/kg/day on days -6, -5. GVHD prophylaxis: 50 mg/kg ideal body weight (IBW) daily dose will be given on days +3 and +4 post-transplant as an IV infusion over 1-2 hours.
Study: NCT03434041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will self-administer matching placebo as intranasal spray.
Study: NCT04532749
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo tablets.
Study: NCT02324309
Drug: BIOD-531
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02324309
Drug: Humalog Mix 75/25
Normalized name: HumaLOG Mix 75/25
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04531982
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, taken as two blinded tablets once daily by mouth
Study: NCT01575041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cellulose, provided by Microz, Geleen, Netherlands): 8 capsules per day.
Study: NCT01328808
Drug: Acetaminophen/APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: In preterm and term neonates with a GA of 28 weeks or more a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute.~In preterm and term neonates with a GA of less than 28 weeks a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute
Study: NCT04067011
Drug: Doxycycline 100Mg Tablet
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline 100mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 2-9, 22-24 and 32-38.
Study: NCT03939481
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given chemotherapy regimen
Study: NCT01489228
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT00828529
Drug: TMC207
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04228900
Drug: Systematic drug review
Normalized name: Integrase Inhibitors, antiinfectives for systematic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consider altering medication list if the patient has symptoms that may be attributed to adverse drug effects, in particular side effects as nausea, dry mouth or loss of appetite, and if drug-drug interactions or drug-disease interactions are likely to occur. Recommended changes in patient's medication list will be presented for the family physician who will hold the final decision to implement the suggested adjustments.
Study: NCT00931008
Drug: SID530, Taxotere
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75mg/m2
Study: NCT01834768
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02762539
Drug: omega-3 enriched SMOF lipid emusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02652377
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match EDP-494
Study: NCT04488081
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral: 400 mg BID for 7 days.
Study: NCT04126603
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection
Study: NCT00321321
Drug: Sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01425528
Drug: Sapropterin
Normalized name: Sapropterin
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sapropterin will be taken daily for 12 or 24 weeks. Starting dose will be 20mg/kg/day and will increase at the 8 week visit to 30 mg/kg/day. Dosing may be further increased to as high as 40 mg/kg/day in attempt to normalize BH4 levels in CSF. Starting dose for Cohort 2 will be determined from data analysis in Cohort 1.
Study: NCT04372121
Drug: Placebo capsule to match Add-back capsule
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: For oral administration once daily
Study: NCT03070327
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 3000 mg/m2 IV once on day -7 to -2 or low intensity cy/flu (cyclophosphamide 300 mg/m2/day x 3 + fludarabine 30 mg/m2/day x 3) with the last day occurring on day -7 to -2 are the default options for is the default conditioning chemotherapy.
Study: NCT02877134
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo Subcutaneously.
Study: NCT04022239
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01121484
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets taken orally once daily.
Study: NCT03602261
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, weekly
Study: NCT04091451
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of Placebo were administered intramuscularly according to a 0,2 months vaccination schedule, at Day 1 and Month 2.
Study: NCT03885011
Drug: CSF-1
Normalized name: CSF-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: This treatment arm consists of 2 different concentrations of CSF-1. Subjects randomized to the CSF-1 treatment arm will receive their first dose of CSF-1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 arm will now receive a different concentration of CSF-1. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
Study: NCT03885011
Drug: CSF-1 Component #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: This treatment arm consists of 2 different concentrations of CSF-1 Component #1.~Subjects randomized to the CSF-1 Component #1 treatment arm will receive their first dose of CSF-1 Component #1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #1 arm will now receive a different concentration of CSF-1 Component #1. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
Study: NCT03885011
Drug: CSF-1 Component #2
Approvals — FDA: no, EMA: no, PMDA: no
Description: This treatment arm consists of a single concentration of CSF-1 Component #2. Subjects randomized to the CSF-1 Component #2 treatment arm will receive their first dose of CSF-1 Component #2 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #2 arm will continue dosing with the same concentration of CSF-1 Component #2. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
Study: NCT02081118
Drug: HM11260C
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
Study: NCT02081118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for HM11260C
Study: NCT03998683
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as SC injection.
Study: NCT01947660
Drug: Systemic analgesia + Continuous regional anesthesia
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic analgesia + Continuous regional anesthesia, peri neural for the 2 to 4 first days post-operative
Study: NCT01947660
Drug: Systemic analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic analgesia as usual
Study: NCT03928145
Drug: Chlorthalidone 25 mg
Normalized name: chlorthalidone 25 MG
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 25 mg taken orally in the morning for 12 weeks.
Study: NCT03928145
Drug: Amiloride 20 mg
Normalized name: amiloride 20 MG
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amiloride 20 mg taken orally in the morning for 12 weeks.
Study: NCT03928145
Drug: Amiloride 10 mg
Normalized name: amiloride 10 MG
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amiloride 10 mg taken orally in the morning for 12 weeks.
Study: NCT01617317
Drug: Hyperimmune intravenous immunoglobulin
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion of 0.4g/kg of H1N1 2009 H-IVIG
Study: NCT00779558
Drug: Heparin sulfate infusion at 10 units/kg/hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of heparin to prevent central line thrombosis in infants after cardiac surgery
Study: NCT00779558
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of normal saline
Study: NCT00791219
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo capsules taken approximately 30 minutes prior to breakfast
Study: NCT04223791
Drug: DOR/ISL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg DOR/ 0.75 ISL FDC tablet taken orally once daily
Study: NCT04223791
Drug: BIC/FTC/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg BIC, 200 mg FTC, and 25 mg TAF combined in a single tablet, taken orally once daily
Study: NCT04223791
Drug: Placebo to BIC/FTC/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to BIC/FTC/TAF in a single tablet taken orally, once daily
Study: NCT04223791
Drug: Placebo to FDC DOR/ISL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to FDC DOR/ISL in a tablet taken orally, once daily
Study: NCT00931918
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide IV
Study: NCT00931918
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin IV solution
Study: NCT02569398
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One matching placebo tablet orally once daily up to 54 months.
Study: NCT04245839
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide
Study: NCT04245839
Drug: JCAR017
Approvals — FDA: no, EMA: no, PMDA: no
Description: JCAR017
Study: NCT00640796
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide, Fludarabine, Interleukin-2, Mesna
Study: NCT00525265
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be orally administered placebo once daily after breakfast for seven days.
Study: NCT00073827
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo MDI QID
Study: NCT02053545
Drug: Conditioning Regimen & GVHD Prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stratum 1 (Refractory disease, relapse after previous transplant): Radiation Therapy (if patient had prior Central Nervous System (CNS) disease), Clofarabine, Melphalan,Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus and MMF~Stratum 2 (Myeloid in remission): Radiation Therapy (if patient had prior CNS disease), Busulfan, Fludarabine, Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus, MMF~Stratum 3 (Lymphoid in remission): Radiation Therapy (if patient had prior CNS disease), TBI, Fludarabine, Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus, MMF
Study: NCT05298098
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive intravenous infusion of 5% Dextrose Solution (50ml of Dextrose 5%) + Furosemide (250mg of furosemide) administered over one hour twice a day.
Study: NCT02839707
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT03912428
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: COX-2 inhibitor
Study: NCT01108393
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01628848
Drug: SPM 962
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPM 962 transdermal patch once a daily up to 36.0 mg/day
Study: NCT01628848
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo transdermal patch
Study: NCT03227224
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 2 placebo capsules matching JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
Study: NCT01960075
Drug: Fosphenytoin
Normalized name: Fosphenytoin
DrugBank: Fosphenytoin (DB01320)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02975297
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline.
Study: NCT02406027
Drug: JNJ-54861911, 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will self-administer JNJ-54861911 tablet, 10 mg (2\*5 mg), orally, once daily.
Study: NCT02406027
Drug: JNJ-54861911, 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will self-administer 1 tablet of JNJ-54861911, containing 25 mg orally, once daily.
Study: NCT04461925
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: per os
Study: NCT04461925
Drug: Hormones
Normalized name: Other hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: a moderate amount of dexamethasone i/v
Study: NCT04461925
Drug: Anticoagulant Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-Q
Study: NCT00129506
Drug: methotrexate + misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03782376
Drug: Placebo (SC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive SC injection of placebo at Week 0.
Study: NCT01430078
Drug: ASP015K
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT01430078
Drug: ASP015K
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution via oral capsule
Study: NCT03019198
Drug: Placebo - Concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00285493
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02780830
Drug: AZD2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2014 will be supplied as oral tablets. AZD2014 will be taken orally twice per day on an intermittent dosing schedule, 2 days on and 5 days off of each week.
Study: NCT03782376
Drug: Placebo (IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive IV infusion of placebo at Week 0.
Study: NCT02659098
Drug: CNTO 2476 3.0 x 10^5 cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single subretinal administration of CNTO 2476 3.0 x 10\^5 cells in 50 microliter (mcL) given by subretinal Delivery System.
Study: NCT00486135
Drug: XL147 (SAR245408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin capsules supplied in 25-mg and 100-mg dosage strengths
Study: NCT00486135
Drug: XL147 (SAR245408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets supplied as 100-mg, 150-mg, and 200-mg dosage strengths
Study: NCT00274690
Drug: GW679769
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00262288
Drug: i.v. recombinant human C1 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03556358
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m\^2, 30 min IV infusion, every 3 weeks (Cycles 1-4)
Study: NCT04487080
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo orally.
Study: NCT03559192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered as 2 capsules orally once daily.
Study: NCT00198601
Drug: Gentamicin in Uniject Pre-filled syringe
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02493868
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimization Phase: Transferred-entry participant will self-administer intranasal placebo at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Maintenance Phase: Direct-entry and transferred-entry participants assigned to placebo will self-administer matching intranasal placebo once weekly or once based on depressive symptoms.
Study: NCT00429442
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg once daily
Study: NCT00429442
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: calcium tablets once daily
Study: NCT03818035
Drug: Placebo Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants of group 2b will receive matching placebo injection subcutaneously at weeks 28, 44 and 60.
Study: NCT03517722
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching to ustekinumab IV or SC.